MRSP in Dogs: Methicillin-Resistant Skin Infections Explained

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated June 2026  ·  10 min read

Photo by Anya Prygunova on Unsplash

Methicillin-resistant Staphylococcus pseudintermedius, commonly abbreviated MRSP, represents one of the most significant emerging challenges in veterinary dermatology. S. pseudintermedius is the primary bacterial pathogen in canine skin infections, residing as a normal commensal on the skin and mucous membranes of most healthy dogs. When this organism acquires methicillin resistance through the mecA gene, it becomes resistant to the entire beta-lactam antibiotic class, which includes the most commonly prescribed drugs for canine pyoderma: cephalexin, amoxicillin-clavulanate, and cefpodoxime.

The prevalence of MRSP has increased dramatically over the past two decades. While it was rarely identified before 2005, it now accounts for 10 to 30 percent of staphylococcal isolates from canine skin infections at referral hospitals and 5 to 15 percent in general practice. Many MRSP strains are resistant to additional antibiotic classes including fluoroquinolones, macrolides, lincosamides, tetracyclines, and trimethoprim-sulfamethoxazole, leaving very few systemic treatment options.

Despite these alarming statistics, MRSP infections are manageable with a systematic approach that emphasizes culture-guided therapy, topical antiseptics, and rigorous control of underlying disease. This article provides a comprehensive overview of MRSP in dogs, from the microbiology of resistance to practical treatment strategies that veterinarians and owners can implement.

What Is MRSP and How Does It Differ from MRSA?

Staphylococcus pseudintermedius: The Canine Staphylococcus

S. pseudintermedius is a coagulase-positive Staphylococcus species that is the primary commensal and pathogenic staphylococcal species in dogs, analogous to S. aureus in humans. It colonizes the nasal mucosa, oropharynx, and skin of 60 to 90 percent of healthy dogs without causing disease. When the skin barrier is compromised by allergies, trauma, or immune dysfunction, S. pseudintermedius transitions from commensal to pathogen, causing superficial and deep pyoderma, wound infections, and otitis externa. Understanding this commensal-to-pathogen transition is essential because eradication of S. pseudintermedius from the body is neither feasible nor desirable. The goal of treatment is to control pathogenic overgrowth while preserving the normal flora.

The mecA Gene and Methicillin Resistance

Methicillin resistance in staphylococci is conferred by the mecA gene, which encodes a modified penicillin-binding protein called PBP2a. Normal penicillin-binding proteins are the targets of beta-lactam antibiotics, and when the drug binds to them, it disrupts cell wall synthesis, killing the bacterium. PBP2a has an altered active site that beta-lactam antibiotics cannot bind, rendering the entire drug class ineffective. The mecA gene is carried on a mobile genetic element called the staphylococcal cassette chromosome mec (SCCmec), which can be transferred between staphylococcal species. This means resistance can spread between bacterial populations.

MRSP vs MRSA: Key Differences

While MRSP and MRSA (methicillin-resistant S. aureus) share the mecA resistance mechanism, they are distinct organisms with different host associations. MRSA is primarily a human pathogen that occasionally infects dogs, while MRSP is primarily a canine pathogen that occasionally colonizes humans. MRSP is far more common than MRSA in canine skin infections, outnumbering MRSA by approximately 10 to 1 in most veterinary studies. Importantly, MRSP strains tend to carry more extensive multi-drug resistance than MRSA strains isolated from dogs, making MRSP infections potentially harder to treat with systemic antibiotics.

Diagnosis: Identifying MRSP

When to Suspect MRSP

MRSP should be suspected in any skin infection that fails to respond to first-line beta-lactam antibiotics at appropriate doses and durations, in any recurrent infection in a dog with a history of multiple antibiotic courses, in infections acquired during or shortly after hospitalization, and in deep or spreading infections that worsen despite treatment. Risk factors that increase the probability of MRSP include prior antibiotic exposure within the past six months, surgery or hospitalization within the past year, and contact with other animals known to carry MRSP.

Culture and Sensitivity Testing Protocols

Definitive diagnosis of MRSP requires bacterial culture and sensitivity testing. Samples should be collected from intact pustules when present, or from the leading edge of an active lesion after surface decontamination. For deep pyoderma, tissue biopsy provides a more reliable sample than surface swabs. The laboratory report will identify the organism as S. pseudintermedius and report its susceptibility to a panel of antibiotics. Methicillin resistance may be reported directly (oxacillin susceptibility) or inferred from resistance to cefoxitin, a surrogate marker. Molecular confirmation of the mecA gene by PCR is available at reference laboratories.

Interpreting Multi-Drug Resistance Patterns

MRSP strains frequently exhibit resistance to multiple antibiotic classes beyond the beta-lactams. A typical multi-drug resistant MRSP strain may be resistant to fluoroquinolones (enrofloxacin, marbofloxacin), macrolides (erythromycin), lincosamides (clindamycin), tetracyclines, trimethoprim-sulfamethoxazole, and aminoglycosides. Drugs that may retain activity include chloramphenicol, rifampin, amikacin, and doxycycline, although susceptibility varies by strain. The culture report guides the selection of the least toxic, most practical effective option.

MRSP remains susceptible to chlorhexidine, making topical therapy essential for these resistant infections.

Photo by Tima Miroshnichenko on Pexels

Treatment Strategies for MRSP Infections

Topical Chlorhexidine: The Cornerstone

Topical chlorhexidine therapy is the single most important treatment modality for MRSP skin infections. Chlorhexidine kills staphylococci, including MRSP, by disrupting cell membrane integrity, a mechanism that is unaffected by the mecA gene or any of the other resistance mechanisms these organisms carry. Multiple in vitro studies have confirmed that MRSP strains remain fully susceptible to chlorhexidine at concentrations achievable with topical products. For superficial pyoderma caused by MRSP, topical chlorhexidine therapy alone may be sufficient, avoiding the need for systemic antibiotics entirely. This approach is recommended by the International Society for Companion Animal Infectious Diseases (ISCAID) as a preferred strategy.

Systemic Antibiotic Selection When Necessary

For deep pyoderma, furunculosis, or widespread MRSP infections, systemic antibiotics guided by culture results are necessary. Chloramphenicol is effective against many MRSP strains but requires regular monitoring of blood counts due to potential bone marrow suppression. Rifampin has excellent skin penetration and activity against many MRSP strains but must always be combined with another antibiotic to prevent rapid resistance development. Doxycycline retains activity against some MRSP strains and has a favorable safety profile. Amikacin, an injectable aminoglycoside, is reserved for severe, life-threatening infections. The choice depends on the individual culture results, the dog's health status, and the feasibility of monitoring.

Combination Topical and Systemic Therapy

The optimal approach for deep MRSP infections combines culture-guided systemic antibiotics with aggressive topical chlorhexidine therapy. The topical component addresses surface bacteria and biofilms that systemic antibiotics may not penetrate, while the systemic antibiotics target deep-tissue infection. This combination approach produces faster resolution, lower relapse rates, and may allow shorter systemic antibiotic courses. Medicated baths with chlorhexidine shampoo two to three times weekly, supplemented by daily spot application of chlorhexidine spray to active lesions, provides comprehensive topical coverage.

Duration of Treatment and Monitoring

MRSP infections typically require longer treatment courses than susceptible infections. Superficial pyoderma should be treated for a minimum of three to four weeks or until two weeks beyond complete clinical resolution. Deep pyoderma requires six to eight weeks or longer. Cytology should be rechecked at two-week intervals to confirm improvement. Culture may be repeated at four weeks to document continued susceptibility, particularly if a drug like rifampin is used. Premature discontinuation of therapy is the most common cause of treatment failure and should be strictly avoided.

The Role of Chlorhexidine Against MRSP

Mechanism of Action

Chlorhexidine is a biguanide antiseptic that works by binding to negatively charged bacterial cell membranes, disrupting their integrity and causing leakage of intracellular contents. At low concentrations, it is bacteriostatic, inhibiting growth. At the higher concentrations achieved with topical products, typically 2 to 4 percent, it is rapidly bactericidal. This physical disruption mechanism is fundamentally different from the targeted enzyme inhibition employed by antibiotics, which is why resistance to chlorhexidine is extremely rare and has not been documented at clinically significant levels in canine staphylococci.

Evidence for Efficacy Against MRSP

Multiple peer-reviewed studies have evaluated chlorhexidine activity against MRSP. A 2012 study in the Irish Veterinary Journal found that chlorhexidine maintained bactericidal activity against all tested MRSP isolates at concentrations well below those achieved by commercial topical products. Similar results have been reported by research groups in Europe and North America. In a clinical trial comparing topical chlorhexidine therapy to systemic antibiotics for superficial pyoderma, including cases caused by resistant organisms, topical therapy achieved equivalent clinical cure rates with significantly lower overall antibiotic consumption.

Practical Application Protocols

For MRSP skin infections, apply chlorhexidine spray directly to all affected areas two to three times daily, ensuring the product contacts the skin surface and is not merely applied to the overlying hair coat. For dogs with thick coats, parting the hair or clipping the affected area improves contact. Allow the product to dry naturally without wiping or rinsing. For widespread disease, supplement spot treatment with full-body medicated baths using chlorhexidine shampoo two to three times weekly, leaving the lather in contact with the skin for a minimum of 10 minutes. Continue topical therapy for the full duration of treatment, even after lesions appear resolved.

Transmission and Infection Control

Dog-to-Dog Transmission

MRSP can be transmitted between dogs through direct contact, shared bedding, grooming equipment, and contaminated environmental surfaces. In multi-dog households, colonization of all dogs is common once one dog is identified as an MRSP carrier. Dogs in close contact, such as those in boarding facilities, grooming salons, dog daycare, and veterinary hospitals, face increased transmission risk. Newly adopted dogs or dogs returning from hospitalization should be monitored for skin infections and cultured if lesions develop.

Transmission to Humans

Humans can be transiently colonized with S. pseudintermedius, including MRSP, through direct contact with colonized or infected dogs. However, S. pseudintermedius is not well-adapted to humans, and sustained colonization is uncommon. Human infections with MRSP are rare but have been reported, primarily in immunocompromised individuals or those with skin wounds. Standard hygiene precautions, including hand washing after handling infected areas, wearing gloves during wound care, and washing contaminated bedding separately, effectively reduce transmission risk.

Environmental Decontamination

S. pseudintermedius can survive on environmental surfaces for days to weeks. During and after treatment of an MRSP infection, launder all dog bedding, blankets, and fabric items in hot water. Disinfect hard surfaces that the dog contacts using a dilute bleach solution or commercial quaternary ammonium disinfectant. Discard any grooming tools that cannot be adequately sterilized. These environmental measures reduce the reservoir of resistant organisms and lower the risk of reinfection or transmission to other animals in the household.

Prevention and Long-Term Management

Reducing Antibiotic Selection Pressure

The most effective long-term strategy for combating MRSP is reducing unnecessary antibiotic use. Every unnecessary antibiotic course creates selection pressure that favors resistant organisms. Adopting a topical-first approach for superficial pyoderma, using culture-guided therapy for recurrent or deep infections, and completing full antibiotic courses at appropriate doses all contribute to slower resistance development. The goal is not to eliminate antibiotic use entirely, but to use antibiotics judiciously and only when they are truly needed.

Controlling Underlying Disease

MRSP infections almost always develop secondary to an underlying condition that compromises the skin barrier or immune system. Uncontrolled atopic dermatitis is the most common predisposing condition. Aggressive management of allergies through immunotherapy, appropriate medications, and environmental controls reduces the frequency of secondary infections and the need for antibiotic therapy. Regular topical antiseptic maintenance between infection episodes helps keep bacterial populations at manageable levels.

Decolonization Considerations

Because S. pseudintermedius is a normal commensal in dogs, complete decolonization is not feasible or recommended for most patients. However, for dogs with recurrent MRSP infections, short-term decolonization protocols using topical chlorhexidine bathing combined with mupirocin or chlorhexidine applied to the nostrils and mouth have been evaluated. These protocols may temporarily reduce the MRSP burden and are sometimes used before elective surgery or in multi-pet households where transmission is a concern. Long-term efficacy of decolonization is limited, as recolonization typically occurs within weeks to months.

MRSP in Dogs FAQ

Q: What does MRSP stand for?

MRSP stands for methicillin-resistant Staphylococcus pseudintermedius. S. pseudintermedius is the most common cause of skin infections in dogs, and methicillin resistance means the bacterium carries the mecA gene, which makes it resistant to all beta-lactam antibiotics, including the most commonly prescribed drugs for canine pyoderma.

Q: Is MRSP the same as MRSA?

No. MRSP and MRSA are different organisms with different primary hosts. MRSA is methicillin-resistant S. aureus, primarily a human pathogen. MRSP is methicillin-resistant S. pseudintermedius, primarily a canine pathogen. MRSP is far more common in dogs than MRSA. While both carry the mecA gene, MRSP strains often have more extensive multi-drug resistance.

Q: Can MRSP be cured?

MRSP skin infections can be successfully treated in most cases using a combination of topical antiseptics and, when necessary, culture-guided systemic antibiotics. However, S. pseudintermedius cannot be permanently eliminated from a dog's body because it is a normal commensal organism. The goal is to control pathogenic infection and prevent recurrence by managing underlying conditions and maintaining skin health.

Q: Can I catch MRSP from my dog?

Human colonization with S. pseudintermedius from dogs is possible but uncommon, and clinical infections in humans are rare. The organism is not well-adapted to humans. Standard hygiene including hand washing after handling infected areas and wearing gloves during wound care provides adequate protection for most people. Immunocompromised individuals should consult their physician.

Q: How can I prevent MRSP from coming back?

Prevention focuses on controlling the underlying condition that predisposes to infection, typically allergies. Consistent allergy management, regular topical antiseptic maintenance with chlorhexidine, and good hygiene practices reduce recurrence risk. Avoid unnecessary antibiotic use, which increases selection pressure for resistant organisms. Complete all prescribed antibiotic courses fully.

Sources

Frank, L.A., & Loeffler, A. (2012). Meticillin-resistant Staphylococcus pseudintermedius: clinical challenge and treatment options. Veterinary Dermatology, 23(4), 283-291.

van Duijkeren, E., et al. (2011). Review on methicillin-resistant Staphylococcus pseudintermedius. Journal of Antimicrobial Chemotherapy, 66(12), 2705-2714.

Hillier, A., et al. (2014). Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis. Veterinary Dermatology, 25(3), 163-e43.

Morris, D.O., et al. (2017). Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals. Veterinary Dermatology, 28(3), 304-e69.

Bryan, J., et al. (2012). Antimicrobial activity of chlorhexidine against staphylococcal isolates from clinical cases in dogs and cats. Irish Veterinary Journal, 65, 10.

Perreten, V., et al. (2010). Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America. Veterinary Microbiology, 141(3-4), 263-271.

Related Reading

• Resistant Dog Skin Infections That Won't Heal, Why some infections resist antibiotics and what to do about it
• Chlorhexidine for Dogs, How this antiseptic works and why it is effective against resistant bacteria
• Pyoderma in Dogs, Comprehensive guide to bacterial skin infections in dogs
• Managing Multiple Skin Conditions, How to handle overlapping conditions that complicate infection treatment

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.